Supplementary Table 8.

Sensitivity analysis by omitting non-randomized studies (without the Li et al., 2015 study).

Original analysisSensitivity analysis
OutcomenEffect (95% CI)PnEffect (95% CI)P
Treatment duration (months)7MD: –0.55 (–3.73, 2.63)0.732MD: 2.69 (–4.97, 10.35)0.49
ABO-OGS total score2MD: 13.38 (9.45, 17.31)<0.0010-
ABO-OGS failure (score>30)2RR: 1.63 (1.24, 2.13)<0.0010-
ABO-OGS component: alignment2MD: 2.60 (–0.48, 5.69)0.100-
ABO-OGS component: marginal ridges2MD: 0.60 (–0.22, 1.43)0.150-
ABO-OGS component: buccolingual inclination2MD: 1.14 (0.21, 2.07)0.020-
ABO-OGS component: occlusal contacts2MD: 4.45 (2.72, 6.18)<0.0010-
ABO-OGS component: occlusal relationship2MD: 1.39 (–0.12, 2.89)0.070-
ABO-OGS component: overjet2MD: 2.61 (1.29, 3.93)<0.0010-
ABO-OGS component: interproximal contacts2MD: 0.02 (–0.17, 0.21)0.830-
ABO-OGS component: root angulation2MD: 0.87 (0.46, 1.28)<0.0010-
PAR post-Tx2MD: –0.03 (–2.02, 1.96)0.980-
PAR reduction via Tx3MD: –1.76 (–3.62, 0.10)0.060-
Original analysisSensitivity analysis
OutcomenEffect (95% CI)PnEffect (95% CI)P
Treatment duration (months)7MD: –0.55 (–3.73, 2.63)0.732MD: 2.69 (–4.97, 10.35)0.49
ABO-OGS total score2MD: 13.38 (9.45, 17.31)<0.0010-
ABO-OGS failure (score>30)2RR: 1.63 (1.24, 2.13)<0.0010-
ABO-OGS component: alignment2MD: 2.60 (–0.48, 5.69)0.100-
ABO-OGS component: marginal ridges2MD: 0.60 (–0.22, 1.43)0.150-
ABO-OGS component: buccolingual inclination2MD: 1.14 (0.21, 2.07)0.020-
ABO-OGS component: occlusal contacts2MD: 4.45 (2.72, 6.18)<0.0010-
ABO-OGS component: occlusal relationship2MD: 1.39 (–0.12, 2.89)0.070-
ABO-OGS component: overjet2MD: 2.61 (1.29, 3.93)<0.0010-
ABO-OGS component: interproximal contacts2MD: 0.02 (–0.17, 0.21)0.830-
ABO-OGS component: root angulation2MD: 0.87 (0.46, 1.28)<0.0010-
PAR post-Tx2MD: –0.03 (–2.02, 1.96)0.980-
PAR reduction via Tx3MD: –1.76 (–3.62, 0.10)0.060-

ABO-OGS, objective grading system of the American Board of Orthodontics; CI, confidence interval; MD, mean difference; PAR, peer assessment rating; RR, relative risk; Tx, treatment.

Supplementary Table 8.

Sensitivity analysis by omitting non-randomized studies (without the Li et al., 2015 study).

Original analysisSensitivity analysis
OutcomenEffect (95% CI)PnEffect (95% CI)P
Treatment duration (months)7MD: –0.55 (–3.73, 2.63)0.732MD: 2.69 (–4.97, 10.35)0.49
ABO-OGS total score2MD: 13.38 (9.45, 17.31)<0.0010-
ABO-OGS failure (score>30)2RR: 1.63 (1.24, 2.13)<0.0010-
ABO-OGS component: alignment2MD: 2.60 (–0.48, 5.69)0.100-
ABO-OGS component: marginal ridges2MD: 0.60 (–0.22, 1.43)0.150-
ABO-OGS component: buccolingual inclination2MD: 1.14 (0.21, 2.07)0.020-
ABO-OGS component: occlusal contacts2MD: 4.45 (2.72, 6.18)<0.0010-
ABO-OGS component: occlusal relationship2MD: 1.39 (–0.12, 2.89)0.070-
ABO-OGS component: overjet2MD: 2.61 (1.29, 3.93)<0.0010-
ABO-OGS component: interproximal contacts2MD: 0.02 (–0.17, 0.21)0.830-
ABO-OGS component: root angulation2MD: 0.87 (0.46, 1.28)<0.0010-
PAR post-Tx2MD: –0.03 (–2.02, 1.96)0.980-
PAR reduction via Tx3MD: –1.76 (–3.62, 0.10)0.060-
Original analysisSensitivity analysis
OutcomenEffect (95% CI)PnEffect (95% CI)P
Treatment duration (months)7MD: –0.55 (–3.73, 2.63)0.732MD: 2.69 (–4.97, 10.35)0.49
ABO-OGS total score2MD: 13.38 (9.45, 17.31)<0.0010-
ABO-OGS failure (score>30)2RR: 1.63 (1.24, 2.13)<0.0010-
ABO-OGS component: alignment2MD: 2.60 (–0.48, 5.69)0.100-
ABO-OGS component: marginal ridges2MD: 0.60 (–0.22, 1.43)0.150-
ABO-OGS component: buccolingual inclination2MD: 1.14 (0.21, 2.07)0.020-
ABO-OGS component: occlusal contacts2MD: 4.45 (2.72, 6.18)<0.0010-
ABO-OGS component: occlusal relationship2MD: 1.39 (–0.12, 2.89)0.070-
ABO-OGS component: overjet2MD: 2.61 (1.29, 3.93)<0.0010-
ABO-OGS component: interproximal contacts2MD: 0.02 (–0.17, 0.21)0.830-
ABO-OGS component: root angulation2MD: 0.87 (0.46, 1.28)<0.0010-
PAR post-Tx2MD: –0.03 (–2.02, 1.96)0.980-
PAR reduction via Tx3MD: –1.76 (–3.62, 0.10)0.060-

ABO-OGS, objective grading system of the American Board of Orthodontics; CI, confidence interval; MD, mean difference; PAR, peer assessment rating; RR, relative risk; Tx, treatment.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close